Highest-materiality recent filing
Teleflex prices $500M 5.875% senior notes due 2032 to refinance 2027 notes
Priced $500M aggregate principal of 5.875% senior notes due 2032 at 100% of par.
Teleflex announces $500M senior notes offering to refinance 2027 notes
Teleflex commenced offering of $500M senior notes due 2032; proceeds plus cash to redeem all $500M of 4.625% notes due 2027.
Teleflex enters $2.2B new credit facilities; $1B revolver and $1.2B term loans
Entered new $1B revolver, $500M term A-1, and $700M term A-2 credit facilities; refinances prior credit agreement.
Teleflex stockholders re-elect all seven directors and approve say-on-pay at 2026 annual meeting
All seven director nominees received >96% of votes cast (excluding broker non-votes).
Teleflex Q1 revenue up 5.1% pro forma; GAAP EPS $(0.11); maintains FY26 guidance
Revenue from continuing ops $548.3M, up 32.3% reported, +5.1% pro forma adjusted constant currency.
Teleflex appoints Jason Weidman as President and CEO effective June 8, 2026
Weidman succeeds interim CEO Stuart Randle, who remains on the board; Weidman to join board on start date.
Sale transactions of Acute Care, Interventional Urology, and OEM on track for H2 2026 close.
Teleflex updates on OEM and Acute Care divestitures; FTC Second Request for urology deal
OEM HSR waiting period expired March 13, 2026; closing anticipated in Q3 2026.
GAAP revenue from continuing ops $1,992.7M (+17.2% YoY); adjusted revenue $1,983.7M (+16.3%).
Teleflex enters separation agreement with ex-CEO Kelly; transition period through March 2026
CEO Liam Kelly departed Jan 7, 2026; separation agreement signed Jan 23, 2026.
Teleflex CEO Liam Kelly out, interim CEO Stuart Randle appointed; 2025 revenue guide cut
Liam Kelly departs as President and CEO effective Jan 7, 2026; Stuart Randle appointed interim CEO.
Total cash consideration $2.03B: OEM business to Montagu/Kohlberg for $1.5B; Acute Care and Interventional Urology to Intersurgical for $530M.
Teleflex Reports Q3 2025 Revenue Growth but GAAP Loss; Lowers Full-Year Guidance
GAAP revenue $913.0M up 19.4% YoY; adjusted revenue $892.9M up 16.8% (adjusted constant currency up 15.3%).
Teleflex Q2 adj. EPS $3.73 beats $3.42 YoY; raises FY outlook on BIOTRONIK deal
GAAP revenue $780.9M (+4.2% YoY); adjusted constant currency revenue growth +1.0%.
Amendment to Credit Agreement added $200M in delayed draw term loans, bringing total commitments to $700M.
Teleflex amends bylaws to allow stockholder written consent; annual meeting votes pass
Bylaws amended to remove prohibition on stockholder action by written consent, effective May 9, 2025.
Q1 revenue $700.7M (-5.0% reported, -3.8% adj constant currency); GAAP EPS $2.07, adjusted EPS $2.91 (down from $3.21).
Teleflex enters $300M accelerated share repurchase agreement with JPMorgan
Entered $300M ASR with JPMorgan; initial delivery of shares worth 80% of repurchase price based on Feb 27 close.
Teleflex reports Q4 adj EPS $3.89 (+15%); plans two-company split and BIOTRONIK acquisition
Q4 GAAP EPS from cont. ops. $(2.95) vs $0.66; adj EPS $3.89 vs $3.38 (+15.1%). Full-year adj EPS $14.01.
Teleflex Q3 GAAP EPS $2.36, adj $3.49; cuts FY revenue growth guidance to 2.9-3.4%
Q3 GAAP revenue $764.4M, +2.4% YoY; GAAP diluted EPS $2.36 vs $2.91; adjusted diluted EPS $3.49 vs $3.64.
Teleflex CFO adopts 10b5-1 plan for up to 53,754 shares starting Dec 2024
CFO Thomas Powell entered a 10b5-1 trading plan allowing sale of up to 53,754 shares.
Paid $200M to Bank of America on Aug 5, 2024, for initial delivery of shares valued at 80% of repurchase price based on Aug 1 closing price.
Teleflex Q2 adjusted revenue $763.5M (+2.7%); raises FY adj EPS guidance to $13.80-$14.20
GAAP revenue $749.7M (+0.9% YoY); adjusted revenue $763.5M (+2.7% YoY, +3.4% constant currency).
Teleflex CEO Liam Kelly adopts 10b5-1 plan to sell up to 36,464 shares (9% of holdings)
CEO Liam Kelly entered Rule 10b5-1 plan to sell up to 36,464 shares acquired via options expiring 2025; sales in Nov and Dec 2024.
Teleflex Q1 revenue $737.8M (+3.8% YoY); adjusted EPS $3.21 vs $3.09; raises FY adjusted EPS low end
GAAP diluted EPS from continuing ops $0.33 vs $1.63 prior year, reflecting $1.69 pension settlement charge.
Teleflex Reports Q4 2023 Revenue of $773.9M, Full Year Revenue $2,974.5M; Provides 2024 Guidance
Q4 GAAP diluted EPS from continuing operations was $0.66, down from $1.65 in prior year; adjusted EPS was $3.38 vs $3.52.
On April 30, 2026, Teleflex Incorporated (the “Company”) announced the appointment of Jason Weidman as the Company’s President and Chief Executive Officer, effective as of June 8, 2026 (the “Start Date”), replacing interim President and Chief Executive Officer Stuart A. Randle at that time.
On April 30, 2026, Teleflex Incorporated (the “Company”) announced the appointment of Jason Weidman as the Company’s President and Chief Executive Officer, effective as of June 8, 2026 (the “Start Date”), replacing interim President and Chief Executive Officer Stuart A. Randle at that time.
who on February 24, 2025 informed the Company that he will retire as Executive Vice President and Chief Financial Officer of the Company, effective April 1, 2025.
the Company’s Board of Directors appointed John R. Deren, 57, who has served as the Company’s Corporate Vice President and Chief Accounting Officer since May 2017, to serve as Executive Vice President and Chief Financial Officer of the Company, effective April 2, 2025.
Max materiality 0.90 · Median 0.70 · Most common event earnings